NEW YORK, Dec. 8, 2011 /PRNewswire/ -- Stemline Therapeutics, Inc. today announced that two studies of SL-401, a clinical stage therapeutic being developed in patients with myeloid malignancies, have also demonstrated preclinical activity against a variety of lymphoid malignancies and have been selected for presentation at the upcoming 53rd Annual Meeting of the American Society of Hematology (ASH) to be held in San Diego, CA from December 10-13, 2011.
One study demonstrates that SL-401 potently inhibits the growth of several Hodgkin's lymphoma (HL) cell lines, and has activity against mantle cell lymphoma (MCL), a non-Hodgkin's lymphoma, as well as T-cell acute lymphoblastic leukemia (T-ALL) cell lines. The other study shows that SL-401 is cytotoxic against primary tumor cells obtained from patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare lymphoma with limited treatment options. These results indicate that further evaluation of SL-401 against lymphoid cancers is warranted.
Stemline and its collaborators from NYU Langone Medical Center, Scott and White Memorial Hospital, and the Institut National de la Sante et de la Recherche Medicale will present the posters.
Owen O'Connor, MD, PhD, of NYU Langone Medical Center and a collaborator on these studies, noted: "Patients with recurrent lymphoid malignancies, in particular, Hodgkin's disease, have few viable treatment options. The initial efficacy data with SL-401 are exciting and we look forward to working with Stemline to further explore this agent in animal studies and beyond."
Ivan Bergstein, MD, CEO of Stemline, commented: "SL-401 is currently being developed in patients with myeloid malignancies. These new data provide an additional potential path forward in lymphoid cancers. We look forward to continuing our collaboration with Dr. O'Connor's group as we continue to pursue this opportunity."
Details on the abstracts selected for presentat
|SOURCE Stemline Therapeutics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved